To date, the main therapeutic approach in the management of AD is based on the use of cholinesterase inhibitors, such as tacrine, donepezil, rivastigmine, and galantamine, that also inhibit the formation of Aβ plaques, which counteract the decrease in the concentration of ACh [76]. This evidence concerns the gene BCHE and Alzheimer disease.